Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15567482 | 0.92 | ARG1 (0.39) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| SCHEMBL5928282 | 0.92 | ARG1 (0.39) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| SCHEMBL5928185 | 0.90 | NPSR1 (0.40) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL2082443 | 0.90 | ARG1 (0.38) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL17393020 | 0.89 | NPSR1 (0.39) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL31603457 | 0.82 | CYP4F2 (0.36) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| SCHEMBL31603414 | 0.80 | NPSR1 (0.33) | NPSR1LMNAOPRM1CYP4F2CYP4A11 | |
| SCHEMBL1688435 | 0.78 | — | — | |
| SCHEMBL17393574 | 0.77 | OPRM1 (0.39) | OPRM1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5928435 | 0.77 | OPRM1 (0.39) | OPRM1CYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| WO-2012098033-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | NPSR1 2990/4885LMNA 3072/4885OPRM1 4863/4885 |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | NPSR1 2990/4885LMNA 3072/4885OPRM1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.